Merck to Present New Clinical Data on JANUVIA® (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association | Merck Newsroom Home

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA^® (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74^th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014.

Several analyses of patient data in real-world settings will also be presented.

Merck to Present New Clinical Data on JANUVIA® (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association | Merck Newsroom Home